NEWRON PHARMACEUT. EO-20 Net Asset Momentum
NEWRON PHARMACEUT. EO-20 net asset momentum. NEWRON PHARMACEUT. EO-20 (NP5) recorded a net asset momentum of -863.7% as of December 2025, with net assets of €-11.13 Million EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore NP5 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of NEWRON PHARMACEUT. EO-20 (2021–2025)
Net asset momentum of NEWRON PHARMACEUT. EO-20 from 2021 to 2025. This chart tracks NEWRON PHARMACEUT. EO-20's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is -863.7%, with net assets of €-11.13 Million EUR as of December 2025. See NP5 book value for net asset value and shareholders' equity analysis.
NEWRON PHARMACEUT. EO-20 Net Asset Momentum by Year (2021–2025)
NEWRON PHARMACEUT. EO-20 net asset momentum by year from 2021 to 2025. The table below shows the complete annual net asset history for NEWRON PHARMACEUT. EO-20 from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see NP5 stock market capitalisation.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | €-11.13 Million | €40.05 Million | €51.19 Million | ▼ -863.7% |
| 2024 | €1.46 Million | €63.91 Million | €62.45 Million | ▲ +104.9% |
| 2023 | €-29.91 Million | €25.87 Million | €55.77 Million | ▼ -113.2% |
| 2022 | €-14.03 Million | €37.20 Million | €51.23 Million | ▼ -551.6% |
| 2021 | €3.11 Million | €50.49 Million | €47.38 Million | — |